A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury

PHASE3SuspendedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

March 7, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions

Spinal Cord Injuries

Interventions

DRUG

ES135

ES135 will be administered via intrathecal

Trial Locations (3)

Kaohsiung Veterans General Hospital, Kaohsiung City

Far Eastern Memorial Hospital, New Taipei City

Taipei Veterans General Hospital, Taipei